The estimated Net Worth of Ann M. Hanly is at least $2.3 Million dollars as of 1 April 2024. Dr Hanly owns over 2,711 units of Vir Biotechnology Inc stock worth over $1,034,100 and over the last 4 years he sold VIR stock worth over $339,353. In addition, he makes $922,220 as Exec. VP & Chief Technology Officer at Vir Biotechnology Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Dr D VIR stock SEC Form 4 insiders trading
Dr has made over 6 trades of the Vir Biotechnology Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,711 units of VIR stock worth $27,246 on 1 April 2024.
The largest trade he's ever made was selling 12,296 units of Vir Biotechnology Inc stock on 22 February 2024 worth over $123,575. On average, Dr trades about 2,822 units every 107 days since 2021. As of 1 April 2024 he still owns at least 132,069 units of Vir Biotechnology Inc stock.
You can see the complete history of Dr Hanly stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Ann M. Hanly Ph.D. biography
Dr. Ann M. Hanly Ph.D. is the Exec. VP & Chief Technology Officer at Vir Biotechnology Inc.
What is the salary of Dr D?
As the Exec. VP & Chief Technology Officer of Vir Biotechnology Inc, the total compensation of Dr D at Vir Biotechnology Inc is $922,220. There are 7 executives at Vir Biotechnology Inc getting paid more, with George Scangos having the highest compensation of $3,944,610.
How old is Dr D?
Dr D is 51, he's been the Exec. VP & Chief Technology Officer of Vir Biotechnology Inc since . There are 16 older and 5 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.
What's Dr D's mailing address?
Ann's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158.
Insiders trading at Vir Biotechnology Inc
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I..., and Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.
What does Vir Biotechnology Inc do?
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
What does Vir Biotechnology Inc's logo look like?
Complete history of Dr Hanly stock trades at Vir Biotechnology Inc
Vir Biotechnology Inc executives and stock owners
Vir Biotechnology Inc executives and other stock owners filed with the SEC include:
-
George Scangos,
President, Chief Executive Officer, Director -
Howard Horn,
Chief Financial Officer, Secretary -
Herbert Virgin,
Executive Vice President of Research and Chief Scientific Officer -
Vicki Sato,
Independent Chairman of the Board -
Dr. Herbert W. Virgin IV, M.D., Ph.D.,
Exec. VP of Research & Chief Scientific Officer -
Dr. Herbert W. Virgin IV,
Exec. VP of Research & Chief Scientific Officer -
Dr. George A. Scangos Ph.D.,
Pres, CEO & Director -
Dr. Ann M. Hanly Ph.D.,
Exec. VP & Chief Technology Officer -
Phil Pang,
Chief Medical Officer -
Dr. George A. Scangos,
Pres, CEO & Director -
Dr. Phillip Pang M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Steven J. Rice,
Chief Admin. Officer -
Saira Ramasastry,
Independent Director -
Robert Perez,
Independent Director -
Phillip Sharp,
Independent Director -
Dr. Klaus Frueh,
Co-Founder & Scientific Advisor -
Robert More,
Independent Director -
Dipchand Nishar,
Independent Director -
Robert Nelsen,
Independent Director -
Elliott Sigal,
Independent Director -
Janet Napolitano,
Director -
Michael Kamarck,
Chief Technology Officer -
Jay Parrish,
Chief Business Officer -
Johanna Friedl-Naderer,
Exec. VP & COO -
Irene Pleasure J.D., Ph.D.,
Sr. VP & Gen. Counsel -
Heather Rowe Armstrong,
VP of Investor Relations -
Dr. Aine M. Hanly Ph.D.,
Chief Technology Officer -
Dr. Louis J. Picker M.D.,
Co-Founder & Scientific Advisor -
Dr. Klaus Frueh Ph.D.,
Co-Founder & Scientific Advisor -
Dr. Neera Dahiya Ravindran M.D., MBA,
VP and Head of Investor Relations & Strategic Communications -
Dr. Louis J. Picker,
Co-Founder & Scientific Advisor -
Dr. Lawrence Corey,
Co-Founder & Scientific Advisor -
Permanent Fund Corp Alaska,
-
& Melinda Gates Foundation ...,
-
Johanna Friedl Naderer,
EVP & Chief Operating Officer -
Steven J. Rice,
Chief Administrative Officer -
Venture Partners Ix, Llcarc...,
-
Endurance (Cayman) Ltd Sb I...,
-
Dhabi Investment Authority ...,
-
Holdings (Private) Ltd Full...,
-
Program Ii (Co Invest Holdi...,
-
Mark Eisner,
EVP and Chief Medical Officer -
Klaus Frueh,
Director -
Venture Partners Ix, Llcarc...,
-
Kristina Burow,
Director -
Jeffrey S. Hatfield,
Director -
Norbert W Bischofberger,
Director -
Ramy Farid,
Director -
Sung Lee,
EVP & Chief Financial Officer -
Ann M. Hanly,
EVP & Chief Technology Officer -
Backer Marianne De,
Chief Executive Officer